Squalene Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Squalene occupies a niche but strategically important segment within the broader specialty chemicals and cosmetic ingredients market. The market has shown steady expansion, with 2025 valuations ranging from approximately USD 150 million to USD 185 million across industry assessments, and the 2026 market size settling around USD 189 million. Long-term projections place the market between USD 240 million and USD 420 million by the early 2030s, depending on the source and underlying assumptions about demand trajectories.

• •2026 market valued at approximately USD 189 million, up from roughly USD 173-185 million in 2025
• •Long-term projections range from USD 243 million to USD 437 million by 2032-2035 across various research assessments
• •Reported CAGR estimates vary between approximately 6.6% and 10.9% depending on methodology and forecast horizon

The cosmetics and personal care sector represents the largest end-use driver, where squalene and its hydrogenated derivative squalane are prized as emollients, moisturizers, and skin-conditioning agents with excellent biocompatibility. Pharmaceutical demand, particularly for squalene-based adjuvants used in influenza and other vaccines, provides a secondary demand pillar that can exhibit episodic surges during pandemic or mass vaccination campaigns. Consumer preference for naturally derived and vegan cosmetic ingredients is accelerating investment in plant-based squalene production routes.

• •Rising demand for natural and plant-derived cosmetic ingredients is shifting production toward olive oil, amaranth, and yeast-based sourcing
• •Pharmaceutical applications, especially vaccine adjuvant formulations, contribute a stable institutional demand base alongside seasonal spikes
• •Growth in the dietary supplements and nutraceuticals sector adds a third demand vector for high-purity squalene

The market is commonly segmented by grade, cosmetic-grade, pharmaceutical-grade, and food/nutrition-grade, each commanding distinct pricing tiers and regulatory requirements. Cosmetic-grade squalene dominates by volume, driven by global personal care consumption, while pharmaceutical-grade occupies a smaller but higher-value niche requiring stringent purity certification. Geographically, production capacity has historically concentrated in regions with access to shark liver oil fisheries and olive oil processing infrastructure, with East Asia and the Mediterranean basin as key origins, though new production facilities are emerging in North America and Europe.

• •Cosmetic-grade squalene holds the largest market share, driven by the global personal care and skincare industry
• •Pharmaceutical-grade squalene commands premium pricing due to stringent purity requirements for vaccine adjuvant and drug delivery applications
• •Production and sourcing capacity is concentrated in East Asia and Mediterranean regions, with plant-based capacity expanding in North America and Western Europe

Who are the notable companies in the industry?

The global squalene market exhibits a moderately concentrated structure, with a relatively small number of established producers controlling a significant share of global capacity, particularly in traditional shark-oil-derived supply chains. The industry features a mix of vertically integrated operations that control sourcing, refining, and downstream formulation, alongside specialty chemical producers that focus on purification and distribution rather than raw material extraction. A notable structural dynamic is the coexistence of two distinct production routes: the incumbent animal-derived pathway and a rapidly growing plant-based and fermentation-derived segment, with the latter gaining market share on sustainability and regulatory grounds in certain jurisdictions.

• •Market is moderately concentrated with a limited number of established producers dominating traditional supply chains, particularly in East Asian and European markets
• •Competitive structure spans integrated producers with upstream sourcing and refining capabilities and specialty processors focused on purification and formulation-grade output
• •Two primary production routes, deep-sea shark liver oil extraction and plant-based/fermentation-derived methods, represent competing technological pathways with shifting market share

What are the recent trends and outlook?

The industry is undergoing a structural transition toward plant-based and yeast-fermentation-derived squalene, driven by regulatory pressure on shark harvesting, consumer sustainability preferences, and the need for supply chain traceability in cosmetic and pharmaceutical applications. Technological improvements in olive oil byproduct refining and microbial fermentation are steadily reducing the cost premium of plant-derived squalene, narrowing the gap with animal-sourced equivalents. Looking ahead, the market is expected to continue its growth trajectory through the early 2030s, with the pace of expansion influenced by regulatory developments in key markets, the evolution of vaccine adjuvant demand, and the ongoing commercial scaling of alternative production technologies.

• •Plant-based and fermentation-derived squalene is gaining market share due to regulatory restrictions on shark-sourced squalene and growing consumer demand for vegan-certified cosmetic ingredients
• •Advances in microbial fermentation and olive oil byproduct refining are improving the cost-competitiveness of sustainable squalene production
• •Market growth through the 2030s will be shaped by regulatory trends, pharmaceutical adjuvant demand cycles, and the commercial viability of next-generation production technologies